Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy
Observational long-term follow-up study of patients who have been exposed to a gene-modified cell therapy produced by ex vivo transduction of immune cells expressing viral or non-viral vectors in studies sponsored by Sorrento Therapeutics, Inc.
Purpose of Study
Study STI-CELL-102 is an observational study of patients who have been exposed to a gene-modified cell therapy (GMCT) produced by ex vivo transduction of immune cells expressing viral and/or non-viral vectors in studies sponsored by Sorrento Therapeutics, Inc. Patients are to be followed for up to 15 years after exposure to a GMCT agent for the possible development of long-term adverse events and efficacy outcomes.
Eligibility
Sex:
AllKey Inclusion / Exclusion Criteria
Inclusion Criteria:
Patients must have received any amount of a CGT in a study sponsored by Sorrento Therapeutics, Inc.
Exclusion
Exclusion Criteria:
Unable or unwilling to provide written informed consent and/or comply with study requirements.
Conditions:
Status:
Enrolling by invitation
Study ID
NCT05472649
Read Detailed Summary
Start Date / End Date:
16/06/2021 -
Enrollment:
1
Full Details:
1 Study Locations
United States
Abramson Cancer Center Clinical Research Unit, University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
